Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA polymerase alpha catalytic subunit (POLA1) is the p180 component of the DNA polymerase α-primase complex. It is essential for initiating DNA replication at origins of replication on both leading and lagging strands, and in synthesizing Okazaki fragments on the lagging strand. It works by extending RNA primers with short stretches of DNA before handing off to more processive polymerases. POLA1 interacts with MCM4, GINS1, retinoblastoma protein (RB), PARP1, and RBMS1. Mutations or dysregulation are associated with X-linked reticulate pigmentary disorder and immune dysfunction.
Inhibition of DNA synthesis (if targeted by a drug)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA polymerase alpha catalytic subunit isoform 1 (POLA1).